CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023

Company Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.

It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.

It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta.

The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014.

CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTI BioPharma Corp.
CTI BioPharma logo
CountryUnited States
Founded1991
IPO DateMar 21, 1997
IndustryBiotechnology
SectorHealthcare
Employees127
CEODr. Adam R. Craig M.B.A., M.D., Ph.D.

Contact Details

Address:
3101 Western Avenue, Suite 800
Seattle, Washington 98121
Phone(206) 282-7100
Websitectibiopharma.com

Stock Details

Ticker SymbolCTIC
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000891293
CUSIP Number12648L601
ISIN NumberUS12648L6011
Employer ID91-1533912
SIC Code2834

Key Executives

NamePosition
Dr. Adam R. Craig M.B.A., M.D., Ph.D.President, Chief Executive Officer, Interim Chief Medical Officer and Director
David H. KirskeExecutive Vice President, Chief Financial Officer and Secretary
Ed BellSenior Director of Investor Relations
James K. FongExecutive Vice President and Chief Commercial Officer
Bruce K. Bennett Jr.Senior Vice President Global Pharmaceutical Operations
John P. VolponeExecutive Vice President and Chief of Staff
Dr. Jennifer A. SmithSenior Vice President of Biometrics

Latest SEC Filings

DateTypeTitle
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023POS AMPost-Effective amendments for registration statement
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments